Maravai LifeSciences
Maravai LifeSciences, a leading provider in the life sciences sector, is headquartered in the United States and operates across key regions globally. Founded in 2016, the company has rapidly established itself as a pivotal player in the biotechnology industry, focusing on critical areas such as nucleic acid production, protein detection, and cell culture solutions. Maravai's core offerings include high-quality reagents and services that support the development of therapeutics and diagnostics. Their unique approach to custom synthesis and scalable production sets them apart in a competitive market. With a commitment to innovation, Maravai has achieved significant milestones, including strategic acquisitions that enhance their capabilities and market reach. Recognised for their excellence, Maravai LifeSciences continues to drive advancements in life sciences, contributing to the global health landscape.
DitchCarbon Score
How does Maravai LifeSciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Maravai LifeSciences's score of 33 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Maravai LifeSciences's reported carbon emissions
In 2024, Maravai LifeSciences reported total carbon emissions of approximately 12,000,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 10,000,000 kg CO2e from purchased goods and services alone. The breakdown of emissions for 2024 includes Scope 1 emissions of about 863,000 kg CO2e and Scope 2 emissions of approximately 2,209,000 kg CO2e (location-based). In 2023, the company recorded total emissions of around 10,000,000 kg CO2e, with Scope 1 emissions at about 737,000 kg CO2e and Scope 2 emissions of approximately 2,027,000 kg CO2e (location-based). The Scope 3 emissions for 2023 were also substantial, particularly from capital goods and purchased goods and services. Maravai LifeSciences has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. However, they continue to monitor and report their emissions across all three scopes, demonstrating a commitment to transparency in their sustainability efforts. The company’s emissions data reflects a growing awareness of the need to address carbon footprints, particularly in the context of their supply chain and operational activities.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 330,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 1,103,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Maravai LifeSciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
